EP3773506A4 - Vésicules comprenant un inhibiteur de pten et leurs utilisations - Google Patents

Vésicules comprenant un inhibiteur de pten et leurs utilisations Download PDF

Info

Publication number
EP3773506A4
EP3773506A4 EP19775863.4A EP19775863A EP3773506A4 EP 3773506 A4 EP3773506 A4 EP 3773506A4 EP 19775863 A EP19775863 A EP 19775863A EP 3773506 A4 EP3773506 A4 EP 3773506A4
Authority
EP
European Patent Office
Prior art keywords
vesicles
same
pten inhibitor
pten
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19775863.4A
Other languages
German (de)
English (en)
Other versions
EP3773506A1 (fr
Inventor
Shulamit Levenberg
Shaowei GUO
Daniel Offen
Nisim PERETS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Technion Research and Development Foundation Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Technion Research and Development Foundation Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of EP3773506A1 publication Critical patent/EP3773506A1/fr
Publication of EP3773506A4 publication Critical patent/EP3773506A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19775863.4A 2018-03-29 2019-03-27 Vésicules comprenant un inhibiteur de pten et leurs utilisations Pending EP3773506A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649648P 2018-03-29 2018-03-29
PCT/IL2019/050355 WO2019186558A1 (fr) 2018-03-29 2019-03-27 Vésicules comprenant un inhibiteur de pten et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3773506A1 EP3773506A1 (fr) 2021-02-17
EP3773506A4 true EP3773506A4 (fr) 2021-12-22

Family

ID=68058075

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19775863.4A Pending EP3773506A4 (fr) 2018-03-29 2019-03-27 Vésicules comprenant un inhibiteur de pten et leurs utilisations

Country Status (7)

Country Link
US (2) US11648260B2 (fr)
EP (1) EP3773506A4 (fr)
JP (1) JP2021519283A (fr)
KR (1) KR20210005031A (fr)
CN (1) CN112236131A (fr)
IL (1) IL277605A (fr)
WO (1) WO2019186558A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504390B2 (en) 2019-03-20 2022-11-22 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
CN111467372B (zh) * 2020-03-03 2022-09-30 中山大学附属第一医院 间充质干细胞外泌体在制备延缓脊髓小脑性共济失调3型病程进展的药物中的应用
EP4132479A1 (fr) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Compositions contenant du cannabidiol et leurs utilisations
CN111748520B (zh) * 2020-06-30 2021-02-19 四川大学 牙囊干细胞外泌体、制法及应用、其组合物及制法
WO2022215078A1 (fr) * 2021-04-07 2022-10-13 Ramot At Tel-Aviv University Ltd. Cannabinoïdes modifiés et leurs utilisations
CN113303280B (zh) * 2021-05-26 2022-11-01 中国人民解放军陆军特色医学中心 建立小鼠腹透腹膜损伤模型的方法及BMSCs外泌体的应用
CN114410632A (zh) * 2022-01-28 2022-04-29 江苏大学 特异性抑制PTEN基因的shRNA及应用
WO2023178500A1 (fr) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Vésicules thérapeutiques et leurs méthodes de traitement
WO2023223312A1 (fr) 2022-05-15 2023-11-23 Nurexone Biologic Ltd. Oligonucléotides d'interférence arn anti-pten et leurs utilisations
WO2024013734A1 (fr) 2022-07-10 2024-01-18 Nurexone Biologic Ltd. Oligonucléotides d'interférence d'arn pour inhiber la formation de réseau périneuronal

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088058A1 (fr) * 2010-01-12 2011-07-21 Alnylam Pharmaceuticals, Inc. Compositions et procédés pouvant inhiber l'expression des gènes du facteur vii et de pten
WO2014152622A1 (fr) * 2013-03-15 2014-09-25 Board Of Regents, The University Of Texas System Biogenèse d'arnmi dans des exosomes à des fins diagnostiques et thérapeutiques
WO2015066701A1 (fr) * 2013-11-04 2015-05-07 Tissuegene, Inc. Traitement de nerf endommagé avec un inhibiteur pten
WO2017161010A1 (fr) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Vésicules membranaires thérapeutiques
WO2017199250A1 (fr) * 2016-05-16 2017-11-23 Exostem Biotec Ltd. Cellule souche mésenchymateuse et son utilisation pour le traitement des lésions musculaires et des maladies associées aux muscles
WO2018022927A1 (fr) * 2016-07-27 2018-02-01 BioAxone BioSciences, Inc. Traitement d'une ateinte du snc avec des moyens thérapeutiques à base d'arni

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (fr) 1988-12-20 2000-02-15 Donald J. Kessler Methode pour obtenir des oligonucleotides synthetiques qui se lient specifiquement a des sites cibles sur des molecules d'adn double brin, en formant un triplex colineaire; methode d'utilisation de ces oligonucleotides synthetiques
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
EP1560931B1 (fr) * 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
EP1638580A2 (fr) 2003-06-27 2006-03-29 atugen AG Induction d'une lyse cellulaire au moyen d'acide ribonucleique a double brin
US20070297985A1 (en) 2006-04-11 2007-12-27 Williams Bart O Method and composition for enhancing bone formation
EP2129397B1 (fr) 2007-03-02 2018-10-31 Amgen, Inc. Procédés et compositions permettant de traiter des maladies tumorales
US20110003008A1 (en) 2008-02-22 2011-01-06 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
US20110189308A1 (en) 2008-03-17 2011-08-04 Asa Abeliovich Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
EP2323695B1 (fr) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes d'acides nucléiques interférents courts
CA2746527A1 (fr) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Emploi d'arni dans des applications dermatologiques
CA2745811C (fr) 2008-12-04 2021-07-13 Joseph Collard Traitement de maladies liees a un gene suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gene
EP2400973B1 (fr) 2009-02-17 2016-11-30 The Trustees of Columbia University in the City of New York Identification de forme extracellulaire de pten qui peut être utilisée pour traiter des tumeurs
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US9127079B2 (en) * 2009-10-16 2015-09-08 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (PTEN) conjugates
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
US10227593B2 (en) 2011-12-13 2019-03-12 Henry Ford Health System Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery
ES2691296T3 (es) 2012-04-03 2018-11-26 Reneuron Limited Micropartículas de células madre
WO2013186735A2 (fr) 2012-06-14 2013-12-19 Bar-Ilan Research And Development Company Ltd. Détection photothermique
WO2015105957A1 (fr) 2014-01-08 2015-07-16 Shriners Hospitals For Children Peptides antagonistes de pten et procédés pour les utiliser
WO2015161184A1 (fr) 2014-04-18 2015-10-22 University Of Massachusetts Chargement d'exosomes avec des oligonucléotides hydrophobiquement modifiés
KR101834841B1 (ko) * 2015-06-01 2018-03-06 아주대학교 산학협력단 줄기세포의 고활성 유도 방법
JP2018520125A (ja) * 2015-06-10 2018-07-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患の処置のためのエキソソームの使用
US11458097B2 (en) 2016-03-30 2022-10-04 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
CN108602849B (zh) * 2016-04-06 2022-10-21 俄亥俄州国家创新基金会 用于通过rna纳米技术将治疗剂特异性递送至细胞的rna配体展示外来体
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
JP7014449B2 (ja) 2016-08-14 2022-02-01 ラモット アット テル アビブ ユニバーシティ， リミテッド 神経障害を処置するための間葉系細胞由来エキソソーム
CN110402146A (zh) 2016-11-03 2019-11-01 埃克森蒂姆生物技术公司 间充质干细胞群、其产物及其用途
JP2020527038A (ja) 2017-07-16 2020-09-03 ラモット アット テル アビブ ユニバーシティ， リミテッド ヒト口腔粘膜幹細胞セクレトーム

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088058A1 (fr) * 2010-01-12 2011-07-21 Alnylam Pharmaceuticals, Inc. Compositions et procédés pouvant inhiber l'expression des gènes du facteur vii et de pten
WO2014152622A1 (fr) * 2013-03-15 2014-09-25 Board Of Regents, The University Of Texas System Biogenèse d'arnmi dans des exosomes à des fins diagnostiques et thérapeutiques
WO2015066701A1 (fr) * 2013-11-04 2015-05-07 Tissuegene, Inc. Traitement de nerf endommagé avec un inhibiteur pten
WO2017161010A1 (fr) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Vésicules membranaires thérapeutiques
WO2017199250A1 (fr) * 2016-05-16 2017-11-23 Exostem Biotec Ltd. Cellule souche mésenchymateuse et son utilisation pour le traitement des lésions musculaires et des maladies associées aux muscles
WO2018022927A1 (fr) * 2016-07-27 2018-02-01 BioAxone BioSciences, Inc. Traitement d'une ateinte du snc avec des moyens thérapeutiques à base d'arni

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG XIAOFEI ET AL: "Mesenchymal stem cells deliver exogenous miR-21 via exosomes to inhibit nucleus pulposus cell apoptosis and reduce intervertebral disc degeneration", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 22, no. 1, 14 August 2017 (2017-08-14), RO, pages 261 - 276, XP055850572, ISSN: 1582-1838, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjcmm.13316> DOI: 10.1111/jcmm.13316 *
LI LUOCHENG ET AL: "Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 479, no. 2, 16 September 2016 (2016-09-16), pages 343 - 350, XP029755052, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2016.09.078 *
SANTEL A ET AL: "RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 13, no. 18, 20 April 2006 (2006-04-20), pages 1360 - 1370, XP002443322, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302778 *

Also Published As

Publication number Publication date
IL277605A (en) 2020-11-30
US20230330130A1 (en) 2023-10-19
WO2019186558A1 (fr) 2019-10-03
EP3773506A1 (fr) 2021-02-17
JP2021519283A (ja) 2021-08-10
RU2020132733A (ru) 2022-04-29
US20210077520A1 (en) 2021-03-18
CN112236131A (zh) 2021-01-15
KR20210005031A (ko) 2021-01-13
US11648260B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
EP3773506A4 (fr) Vésicules comprenant un inhibiteur de pten et leurs utilisations
EP3768664A4 (fr) Inhibiteurs de shp2 et leurs utilisations
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP3746071A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP3746129A4 (fr) Nanocomplexes de type lipide et leurs utilisations
EP4003319A4 (fr) Inhibiteurs de hdac6 et leurs utilisations
EP3629838A4 (fr) Chaise portable et procédés de formation d&#39;une chaise portable
EP3575285A4 (fr) Inhibiteur de lsd1, son procédé de préparation et son application
EP3886798A4 (fr) Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3728257A4 (fr) Inhibiteurs de l&#39;autotaxine et leurs utilisations
EP3753937A4 (fr) Inhibiteur d&#39;atr et son application
EP3820467A4 (fr) Conjugués d&#39;anticorps-inhibiteur alk5 et leurs utilisations
EP3660023A4 (fr) Composé utilisé en tant qu&#39;inhibiteur d&#39;acc et utilisation associée
EP3741758A4 (fr) Composé inhibiteur de bromodomaine et son utilisation
EP3712147B8 (fr) Inhibiteur de sglts et son utilisation
EP4057870A4 (fr) Article de mobilier
EP3796895A4 (fr) Vésicules extracellulaires et leurs utilisations
EP4028385A4 (fr) Inhibiteurs d&#39;usp30 et utilisations de ceux-ci
EP3786156A4 (fr) Inhibiteur de ferroptose 10h-phénothiazine, son procédé de préparation et son utilisation
EP3784650A4 (fr) Nouveaux inhibiteurs de mct4 et leurs utilisations
EP3828184A4 (fr) Dérivé de pyrazolopyrimidine et son utilisation comme inhibiteur de pi3k
EP4038139A4 (fr) Adhésif et procédés d&#39;utilisation
EP3941909A4 (fr) Inhibiteurs de pi4-kinase et leurs procédés d&#39;utilisation
EP3861219A4 (fr) Moyen de verrouillage et meuble le comprenant
EP4027993A4 (fr) Inhibiteurs de cyclo-oxygénase 2 et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/28 20150101ALI20211118BHEP

Ipc: A61K 9/127 20060101ALI20211118BHEP

Ipc: A61K 31/7088 20060101ALI20211118BHEP

Ipc: C12N 15/113 20100101AFI20211118BHEP